Cargando…
UPAR AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN RECURRENT GLIOBLASTOMA
Glioblastoma (GBM) is the common malignant brain tumor in adults, accounting for approximately 15% of all CNS tumors, and 48.6% of malignant brain tumors, with a median survival of approximately 15 months, and minimal clinical progress having been made in the past two decades. GBM is characterized b...
Autores principales: | Maich, William, Shaikh, Vaseem, Puri, Anish, Anand, Alisha, Rosotti, Martin, Savage, Neil, Chokshi, Chirayu, Suk, Yujin, Gwynne, Will, Seyfrid, Mathieu, Venugopal, Chitra, Henry, Kevin, Singh, Sheila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337559/ http://dx.doi.org/10.1093/noajnl/vdad071.041 |
Ejemplares similares
-
CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022) -
A Patient-Derived Xenograft Model of Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2020) -
Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors
por: Tatari, Nazanin, et al.
Publicado: (2022) -
Advances in Immunotherapy for Adult Glioblastoma
por: Chokshi, Chirayu R., et al.
Publicado: (2021) -
SYST-28 FUNCTIONAL MAPPING REVEALS WIDESPREAD REMODELLING AND A NOVEL TARGETABLE PTP4A2-ROBO1 SIGNALING AXIS AT GLIOBLASTOMA RECURRENCE
por: Chokshi, Chirayu, et al.
Publicado: (2023)